Month: May 2025

PHOENIX, May 19, 2025 (GLOBE NEWSWIRE) — Leslie’s, Inc. (NASDAQ: LESL), the largest and most trusted direct-to-customer brand in the U.S. pool and spa care industry serving residential customers and pool professionals nationwide, recently launched its refreshed Pool Perks Rewards Program with the introduction of loyalty tiers. This program is making a splash as pool owners dive into summer focused on ensuring their backyard oasis is clean, safe and beautiful for another season of making memories. “Everything we do at Leslie’s starts with the customer and our industry leading loyalty program is focused on making it easier and more rewarding for residential customers working to keep their pools in pristine condition,” said Jason McDonell, Leslie’s chief executive officer. “Our new tiered Pool Perks Rewards Program is one more way...

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) — Reading International, Inc. (NASDAQ: RDI) (“Reading” or our “Company”), an internationally diversified cinema and real estate company with operations and assets in the United States, Australia, and New Zealand, announced it is scheduled to participate at Sidoti’s Virtual Micro-Cap Investor Conference taking place on Wednesday, May 21, through Thursday, May 22, 2025. Investor Relations contact, Andrzej Matyczynski, Executive Vice President – Global Operations, will present virtually at 10:45 A.M. Eastern time on Thursday, May 22, 2025. The presentation will provide insight on the Company’s financial results for the fiscal first quarter ending March 31, 2025, business outlook and capital allocation strategy. The Company will also host virtual one-on-one investor meetings throughout...

HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) — NCS Multistage Holdings, Inc. (“NCS” or the “Company”) (NASDAQ:NCSM) announced today that Ryan Hummer, Chief Executive Officer, is scheduled to present at the Emerging Growth Conference on Wednesday, May 21, 2025 at 1:55 p.m. Central Time (2:55 p.m. Eastern Time). To attend the presentation, interested parties should register at the following link: Register for Emerging Growth Conference here A recording of the presentation should be available on the Company’s website at www.ncsmultistage.com under the Investors section for approximately 90 days following the event. NCS Multistage Holdings, Inc. is a leading provider of highly engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completions and field development strategies....

SAN FRANCISCO, May 19, 2025 (GLOBE NEWSWIRE) — Opendoor Technologies Inc. (Nasdaq: OPEN) (the “Company”), a leading e-commerce platform for residential real estate transactions, today announced the completion of its negotiated exchange and subscription agreements (the “Exchange and Subscription Agreements”) with certain holders of the Company’s 0.25% Convertible Senior Notes due 2026 (the “2026 Notes”) and new investors, pursuant to which the Company issued $325.0 million aggregate principal amount of its 7.000% Convertible Senior Notes due 2030 (the “2030 Notes”) consisting of (a) approximately $245.8 million principal amount of 2030 Notes issued in exchange for approximately $245.8 million principal amount of 2026 Notes (the “Exchange Transactions”), and (b) approximately $79.2 million principal amount of 2030 Notes for cash...

LAS VEGAS, May 19, 2025 (GLOBE NEWSWIRE) — BitMine Immersion Technologies, Inc. (OTCQX: BMNRD) today announced the launch of its Bitcoin Treasury Advisory Practice, alongside a $4 million strategic transaction with a U.S. exchange-listed company. BitMine is offering “Mining as a Service,” or MaaS, to the strategic partner and plans to offer MaaS to companies that own Bitcoin and wish to add Bitcoin denominated revenue, in addition to Bitcoin, as a core treasury holding.  Upon closing of the strategic agreement, BitMine will lease 3,000 Bitcoin ASIC miners to the client through December 30, 2025, for $3.2 million, with $1.6 million paid upfront. The client has also engaged BitMine for an $800,000 consulting agreement for one year, focused on Bitcoin Mining-as-a-Service and Bitcoin Treasury Strategy. This marks the first...

MOCKSVILLE, N.C., May 19, 2025 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a tobacco products company that is leading the fight against nicotine and believes smokers should have a choice about their nicotine consumption, (the “Company”) is pleased to announce that Larry Firestone, Chief Executive Officer, will present a brief corporate update at the Emerging Growth Conference on Wednesday, May 21, 2025, at 12:00 pm Eastern Time. Mr. Firestone will provide updates to recent company advancements and may subsequently open the floor for questions. Questions may be submitted in advance to Questions@EmergingGrowth.com. Investors can register in advance to attend the conference and receive any updates at: https://goto.webcasts.com/starthere.jsp?ei=1709483&tp_key=7518636947&sti=xxii If attendees are not able to...

-Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, long-acting Factor XI (FXI) small interfering RNA (siRNA) for the treatment of thromboembolic disorders- -SRSD107 demonstrated peak reductions in FXI activity >93% and increases in activated partial thromboplastin time (aPTT) >2x with maintained efficacy up to 6 months post-dosing in a Phase 1 clinical trial- -Under the agreement, CRISPR Therapeutics will make an upfront payment of $25 million in cash and $70 million in equity to Sirius Therapeutics; CRISPR Therapeutics also has rights to exclusively license up to two additional siRNA programs- -Expands CRISPR’s therapeutic toolkit to develop a broader range of transformative gene-based medicines in addition to the gene-editing programs in the clinic- ZUG, Switzerland...

Company’s first development candidate in autoimmune and inflammatory disease (AIID) demonstrates potent blockade of IL-4, IL-13, and IL-33 signaling pathways critical in respiratory inflammation Novel bispecific design shows promising potential manufacturability and stability to support high dosing concentration and subcutaneous administration Regulatory filing to support Phase 1 studies expected in 2H-2026VANCOUVER, British Columbia, May 19, 2025 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the presentation of new preclinical data for ZW1528, a novel IL-4Rα x IL-33 bispecific...

Timothy Kieffer, Ph.D., appointed Chief Scientific Officer Danny Villeneuve appointed Chief Commercial Officer Terrie Kellmeyer, Ph.D., appointed Senior Vice President, Regulatory Affairs Christian Zapf, J.D., appointed General CounselSAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) — Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the appointments of key members of its leadership team, including Timothy Kieffer, Ph.D., as Chief Scientific Officer; Danny Villeneuve as Chief Commercial Officer; Terrie Kellmeyer, Ph.D., as Senior Vice President, Regulatory Affairs; and Christian Zapf, J.D., as General Counsel. “As we make progress...

LAKE FOREST, Ill., May 19, 2025 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that Brendan O’Grady, Chief Executive Officer, will present at the virtual Alliance Global Partners Healthcare Company Showcase, taking place Wednesday, May 21, 2025. Mr. O’Grady’s fireside chat will be webcast live at 11:20 a.m. ET. To join the event, please register at https://us02web.zoom.us/webinar/register/WN_jB1HgKLvQFmUfC6VBT11mw#/registration, or visit the Events & Presentations page at the Company’s investor relations website, https://investor.assertiotx.com/. About Assertio Assertio is a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs. Our focus is on supporting patients by marketing products in...